<DOC>
	<DOCNO>NCT00953537</DOCNO>
	<brief_summary>RATIONALE : Identifying gene increase person 's susceptibility side effect cause capecitabine may help doctor plan good treatment . PURPOSE : This clinical trial study blood sample predict response capecitabine woman metastatic breast cancer .</brief_summary>
	<brief_title>Predicting Response Capecitabine Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine sensitivity , specificity , positive negative predictive value dihydrouracil/uracil ( UH_2/U ) ratio measure start treatment grade 3-4 capecitabine-related toxicity woman metastatic breast cancer . Secondary - To prospectively test value germinal genotype thymidylate synthase ( TS ) methylenetetrahydrofolate reductase ( MTHFR ) predictor resistance capecitabine . - To evaluate practical feasibility pre-therapeutic screening . - To determine sensitivity , specificity , positive negative predictive value dihydropyrimidine dehydrogenase genotyping grade 3-4 capecitabine-related toxicity first second course . - To evaluate predictive gain provide genotyping relative phenotyping alone . - To evaluate influence TS MTHFR gene polymorphism clinical response duration response . - To evaluate pharmacokinetics capecitabine metabolite relationship UH_2/U genotype . - To evaluate total cost pre-therapeutic phenotyping alone combination phenotyping genotyping . - To exhaustively analyze 23 exon dihydropyrimidine dehydrogenase ( DPYD ) gene patient develop toxicity . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect 8-15 day start treatment periodically first day treatment dihydropyrimidine dehydrogenase phenotyping ( dihydrouracil/uracil ratio high performance liquid chromatography analysis ) , genotyping ( 4 relevant single nucleotide polymorphism ) , pharmacokinetic analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiologically ( scintography ) histologically confirm metastatic breast cancer At least 1 measurable evaluable target lesion Receiving capecitabine monotherapy target antiangiogenic therapy ( e.g. , bevacizumab trastuzumab ) No uncontrolled brain metastasis Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Life expectancy â‰¥ 3 month Fertile patient must use effective contraception No chronic uncontrolled illness No congestive heart failure No peripheral venous disease No severe uncontrolled infection No hypoxemic respiratory failure No prior primary cancer except basal cell carcinoma skin No psychologic disorder PRIOR CONCURRENT THERAPY : See Disease Characteristics No capecitabine coadministered chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>